Last edition
News about Global Pharma
India and Switzerland Explore Pharma-Biotech Collaboration After High-Level Meeting
The talks emphasised avenues for Swiss companies to invest in India’s pharma and biotech industries and to leverage the country’s robust healthcare market.
Global Pharma | 28/11/2025 | By Darshana | 178
Valneva to Further Consolidate its Operations in France
The move is part of Valneva’s strategy to optimise its global footprint, enhance operational efficiency in France, and unify all research and development efforts at its Vienna hub.
Global Pharma | 28/11/2025 | By Dineshwori | 271
Novartis to cut 550 jobs in Switzerland as it shifts focus to cell therapy and advanced biologics
Novartis announced plans to eliminate 550 jobs in Switzerland by the end of 2027 as part of a strategic shift toward cell therapy, RNA-based medicines, and other advanced biologics. The cuts will primarily affect its Stein facility, where the company is phasing out the production of pills, capsules, and sterile medicine packaging.
Global Pharma | 27/11/2025 | By Darshana | 433
Glenmark Launches New Fixed-Dose Triple Therapy for COPD
The treatment combines three medications—an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA)—into a single inhaler, aiming to simplify therapy and improve patient adherence.
Global Pharma | 26/11/2025 | By Darshana | 240
Abbott India Gets Central Government Nod for New Managing Director
Abbott India has announced that the Central Government has approved the appointment of Kartik Rajendran as the company’s Managing Director for a five-year term, effective June 14, 2025, to June 13, 2030.
Global Pharma | 24/11/2025 | By Dineshwori | 617
Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration
Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.
Global Pharma | 24/11/2025 | By Dineshwori | 278
Shimadzu Medical Systems USA to Unveil MobileDaRt Evolution MX9 Version
Shimadzu Medical Systems USA is set to unveil the MobileDaRt Evolution MX9 Version at the upcoming RSNA Technical Exhibits in Chicago, showcasing enhanced mobility, improved operator visibility, and instant on-board image verification for faster clinical decisions.
Global Pharma | 24/11/2025 | By Dineshwori | 123
Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma
Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.
Global Pharma | 21/11/2025 | By Dineshwori | 169
State of Texas Sues Bristol-Myers Squibb, Sanofi Over Alleged Failure to Disclose Plavix Efficacy
McKool Smith and The Lanier Law Firm, along with Texas Attorney General Ken Paxton, have filed a lawsuit on behalf of the State of Texas against Bristol-Myers Squibb Company and several Sanofi entities, alleging the companies failed to disclose the efficacy and safety profile of the drug Plavix, which is used as a blood thinner.
Global Pharma | 21/11/2025 | By Dineshwori | 166
Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Global Pharma | 21/11/2025 | By Dineshwori | 241
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy